期刊文献+

仙灵骨葆胶囊联合伊班膦酸钠注射液和碳酸钙D_3治疗老年骨质疏松的临床研究 被引量:14

Clinical study on Xianling Gubao Capsules combined with Sodium Ibandronate Injection and calcium carbonate D_3 in treatment of osteoporosis
原文传递
导出
摘要 目的探讨仙灵骨葆胶囊联合伊班膦酸钠注射液和碳酸钙D_3治疗老年骨质疏松症的临床疗效。方法选取2013年3月—2014年3月郫县人民医院收治的骨质疏松症患者74例,按治疗方法的不同分为对照组和治疗组,每组各37例。对照组患者静脉滴注伊班膦酸钠注射液,2 mg加入生理盐水250 m L,滴注时间≥2 h,3个月1次;同时口服碳酸钙D_3片,1片/d。治疗组在此基础上口服仙灵骨葆胶囊,2粒/次,3次/d。两组患者均治疗12个月。观察两组的临床疗效,同时比较两组治疗前后血钙(S-Ca)、血磷(S-P)、碱性磷酸酶(ALP)、骨密度(BMD)和骨钙素(BGP)的变化情况。结果治疗后,对照组和治疗组的总有效率分别为78.38%、89.19%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者S-P、ALP均显著降低,且S-Ca升高,同组治疗前后差异具有统计学意义(P<0.05);且治疗组上述指标改善程度优于对照组(P<0.05)。治疗后,两组患者腰椎L2-L4 BMD、股骨颈BMD和BGP均显著升高(P<0.05);且治疗组升高更明显,两组比较差异具有统计学意义(P<0.05)。结论仙灵骨葆胶囊联合伊班膦酸钠注射液和碳酸钙D_3治疗老年骨质疏松症疗效确切,可有效增加患者BMD,并能明显改善骨代谢和骨转换状态,具有一定的临床推广应用价值。 Objective To investigate the clinical effect of Xianling Gubao Capsules combined with Sodium Ibandronate Injection and calcium carbonate D_3 in treatment of osteoporosis. Methods Patients(74 cases) with osteoporosis in Pixian People's Hospital from March 2013 to March 2014 were divided into control and treatment groups according to the different treatments, and each group had 37 cases. The patients in the control group were iv administered with Sodium Ibandronate Injection, 2 mg added to normal saline 250 m L, drip time≥2 h, once 3 months. And they were po administered with Calcium Carbonate D_3 Tablets, 1 tablet/d. The patients in the treatment group were po administered with Xianling Gubao Capsules on the basis of control group, 2 grains/time, three times daily. The patients in two groups were treated for 12 months. After treatment, the clinical efficacy was evaluated, and the changes of S-Ca, S-P, ALP, BMD, and BGP in two groups before and after treatment were compared. Results After treatment, the clinical effect in the control and treatment groups were 78.38% and 89.19%, respectively, and there were differences between two groups(P〈0.05). After treatment, S-P and ALP in two groups were significantly decreased, but S-Ca was increased, and the difference was statistically significant in the same group(P〈0.05); The observational indexes in the treatment group were significantly better than those in the control group(P〈0.05). After treatment, L2-L4 BMD femoral neck BMD and BGP were significantly increased, and the difference was statistically significant in the same group(P〈0.05); And the increase degree of these observational indexes in the treatment group was more significantly than those in the control group, with significant difference between two groups(P〈0.05). Conclusion Xianling Gubao Capsules combined with Sodium Ibandronate Injection and calcium carbonate D_3 in treatment of osteoporosis has a good clinical effect, can effectively increase BMD, and improve the bone
出处 《现代药物与临床》 CAS 2016年第7期1067-1070,共4页 Drugs & Clinic
关键词 仙灵骨葆胶囊 伊班膦酸钠注射液 碳酸钙D3片 骨质疏松症 临床疗效 骨代谢指标 骨密度 骨钙素 Xianling Gubao Capsules Sodium Ibandronate Injection Calcium Carbonate D3 Tablets osteoporosis clinical effect bone metabolic indexes BMD BGP
  • 相关文献

参考文献10

  • 1吴非同,胡传来,方炎福,万宇辉,陶兴永,张付坤,陈文胜.社区中老年人群骨质疏松影响因素研究[J].中国全科医学,2011,14(14):1540-1542. 被引量:52
  • 2中国健康促进基金会骨质疏松防治中国白皮书编委会.骨质疏松症中国白皮书.中华健康管理学杂志,2009,3(3):148-156. 被引量:84
  • 3黄多临.仙灵骨葆胶囊治疗骨质疏松症研究述评[J].中医学报,2013,28(2):285-287. 被引量:35
  • 4Goddard J C,Oliver E R,Lambert P R,et al.Prevention of cerebrospinal fluid leak after translabyrinthine resection of vestibular schwannoma[J].Otol Neurotol,2010,31(3):473-477. 被引量:1
  • 5中国人骨质疏松症建议诊断标准(第二稿)[J].中国骨质疏松杂志,2000,6(1):1-3. 被引量:1235
  • 6中华人民共和国卫生部.中药新药治疗骨质疏松症的临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:356.360. 被引量:2
  • 7Ziller V,Kostev K,Kyvernitakis I,et al.Persistence and compliance of medications used in the treatment of osteoporosis-analysis using a large scale,representative,longitudinal German database[J].Int J Clin Pharm Th,2012,50(5):315-322. 被引量:1
  • 8Xu Y,Viswanathan H N,Ward M A,et al.Patterns of osteoporosis treatment change and treatment discontinuation among commercial and medicare advantage prescription drug members in a national health plan[J].J Eval Clin Pract,2013,19(1):50-59. 被引量:1
  • 9Mosekilde L,Vestergaard P,Rejnmark L,et al.The pathogenesis,treatment and prevention of osteoporosis in men[J].Drugs,2012,73(1):15-29. 被引量:1
  • 10Belaya Z E.Should we really compare absolute risk reduction in different trials on osteoporosis:comment on the article by Ringe JD and Doherty JG[J].Rheumatol Int,2010,31(12):1669-1671. 被引量:1

二级参考文献32

  • 1沈薇,谢夏君,储珏.40~65岁妇女骨质疏松症危险因素分析[J].中国全科医学,2009,12(14):1274-1275. 被引量:29
  • 2袁临益,徐招跃,叶子.仙灵骨葆胶囊对原发性骨质疏松症患者的细胞因子及生存质量的影响[J].浙江中医药大学学报,2011,35(5):683-685. 被引量:12
  • 3陈玉平,蔡德鸿,刘雪琴,杨力,汤灵莉,杨玉莲,甘俊丽.社区中老年人骨质疏松症的患病危险因素调查[J].中国临床康复,2005,9(15):156-157. 被引量:13
  • 4Cadarette SM,Jaglal SB,Murray TM,et al.Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry[J].JAMA,2001,286(1):57-63. 被引量:1
  • 5Gregg EW,Kriska AM,Salamone LM,et al.The epidemiology of quantitative ultrasound:a review of the relationships with bone mass,osteoporosis and fracture risk[J].Osteoporos Int,1997,7(2):89-99. 被引量:1
  • 6Taylor BC,Schreiner PJ,Stone KL,et al.Long-term prediction of incident hip fracture risk in elderly white women:study of osteoporotic fractures[J].J Am Geriatr Soc,2004,52(9):1479-1486. 被引量:1
  • 7Schmitt NM,Schmitt J,Doren M.The role of physical activity in the prevention of osteoporosis in postmenopausal women-An update[J].Maturitas,2009,63(1):34-38. 被引量:1
  • 8Arslantas D,Metintas S,Unsal A,et al.Prevalence of osteoporosis in middle anatolian population using calcaneal ultrasonography method[J].Maturitas,2008,59:234-241. 被引量:1
  • 9Xu L,Lu A,Zhao X,et al.Very low rates of hip fracture in Beijing,People's Republic of China the Beijing Osteoporosis Project[J].Am J Epidemiol,1996,144(9):901-907. 被引量:1
  • 10Qin, L. , Zhang, G. , Hung, W. Y.. Phytoestrogen - rich herb formula "XLGB" prevents OVX- induced deterioration of musculoskeletal tissues at the hip in old rats[J]. J Bone Miner Metab,2005,23 (4) : 55 -61. 被引量:1

共引文献1394

同被引文献290

引证文献14

二级引证文献145

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部